Medical News

RSS

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.

2 Nov 2010

PCIS releases ClaimsVISION SaaS delivered claims administration system

PCIS, a proven and trusted provider of policy administration and claims solutions, today announced the release and immediate availability of ClaimsVISION, a highly automated and user configurable, Software as a Service (SaaS) delivered claims administration system.

2 Nov 2010

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo Company today announced results for its first quarter ended September 25, 2010.

2 Nov 2010

Palatin receives $978,000 in grants under PPACA

Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.

2 Nov 2010

AtriCure third quarter revenue increases $1.2 million to $14.5 million

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced revenue of $14.5 million for its seasonally impacted third quarter of 2010. Revenue from product sales in the United States was $11.6 million, reflecting growth of 8.1 percent and international revenue was $2.9 million, reflecting 19.2 percent growth on a constant currency basis or 12.7 percent on a GAAP basis.

2 Nov 2010

Nordson completes Micromedics acquisition

Nordson Corporation today announced the completion of its acquisition of St. Paul, Minnesota-based Micromedics Inc., a leader in applying and dispensing biomaterials for controlling bleeding, healing wounds and other related medical procedures.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

Senesco resolves NYSE Amex continued listing deficiency

Senesco Technologies, Inc. today announced that the Company has received a letter from the NYSE Amex LLC informing Senesco that it has now resolved matters related to the Company's exchange listing compliance.

2 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

West third quarter gross profit increases $3.0 million to $74.7 million

West Pharmaceutical Services, Inc. today announced its financial results for the third quarter of 2010.

2 Nov 2010

GEN co-sponsored roundtable discussion on Gulf Oil Spill

Genetic Engineering & Biotechnology News announced that on Thursday, October 28th, they co-sponsored a roundtable discussion on new ways to use biological solutions to assist in environment cleanup after manmade or natural disasters.

2 Nov 2010

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling $977,917, by the United States Internal Revenue Service (IRS) as part of the Patient Protection and Affordable Care Act of 2010.

2 Nov 2010

Medco third quarter net revenue increases 10.3% to $16.3 billion

Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.

2 Nov 2010

CorVel second quarter EPS increases 24% to $0.62

CorVel Corporation reported earnings per share of $0.62 for the quarter ended September 30, 2010, a 24% increase compared to $0.50 in the same quarter of the prior fiscal year. Earnings per share for the six months ended September 30, 2010 were $1.26, a 27% increase over the $0.99 earnings per share for the six months ended September 30, 2009.

2 Nov 2010

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.

From NanoString Technologies 2 Nov 2010

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.

2 Nov 2010

AmerisourceBergen fiscal fourth quarter revenue increases 5.3% to $19.7 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2010 fourth quarter ended September 30, 2010, diluted earnings per share increased 13.6 percent to $0.50, and revenue increased 5.3 percent to a record $19.7 billion.

2 Nov 2010

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Inhibitex, Inc. announced today that three posters describing preclinical data on INX-189, the Company's nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

2 Nov 2010

Nu Skin third quarter revenues increase 15% to record $383.6 million

Nu Skin Enterprises, Inc. today announced record third-quarter results, with revenue of $383.6 million, a 15 percent improvement over the prior-year period. Quarterly revenue was positively impacted 4 percent by foreign currency fluctuations. Earnings per share for the quarter were $0.55, a 38 percent improvement over the prior year.

2 Nov 2010